Assess whether scientific advice should be sought before the next trial

Situation

A DSMB note on an imbalance that is not yet a signal put phase-3 protocol with endpoint-sensitivity issues in front of labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study. This Pharma & Life Sciences / CMC and Development Pathways close is scientific advice should be from phase-3 protocol with endpoint-sensitivity issues, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• The population in phase-3 protocol with endpoint-sensitivity issues is the one a DSMB note on an imbalance that is not yet a signal named, so Proceed under protocol follows for this CMC and Development Pathways file.
• The population in phase-3 protocol with endpoint-sensitivity issues is adjacent only to a DSMB note on an imbalance that is not yet a signal; Pause the pathway is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained a DSMB note on an imbalance that is not yet a signal before phase-3 protocol with endpoint-sensitivity issues arrived; no new CMC and Development Pathways path.
• Provenance on phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a DSMB note on an imbalance that is not yet a signal.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read phase-3 protocol with endpoint-sensitivity issues against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move scientific advice should be for labeling negotiator.

Recommendation